These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 18194120)

  • 21. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis.
    Ciancio G; Gaynor JJ; Zarak A; Sageshima J; Guerra G; Roth D; Brown R; Kupin W; Chen L; Tueros L; Hanson L; Ruiz P; Burke GW
    Transplantation; 2011 Jun; 91(11):1198-205. PubMed ID: 21107305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alemtuzumab induction in renal transplantation permits safe steroid avoidance with tacrolimus monotherapy: a randomized controlled trial.
    Welberry Smith MP; Cherukuri A; Newstead CG; Lewington AJ; Ahmad N; Menon K; Pollard SG; Prasad P; Tibble S; Giddings E; Baker RJ
    Transplantation; 2013 Dec; 96(12):1082-8. PubMed ID: 24056618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of Early Steroid Withdrawal in Recipients of Deceased-Donor Expanded Criteria Kidney Transplants in the Era of Induction Therapy.
    Hussain SM; Marcus RJ; Ko TY; Nashar K; Thai NL; Sureshkumar KK
    Exp Clin Transplant; 2016 Jun; 14(3):287-93. PubMed ID: 27221720
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
    Offner G; Toenshoff B; Höcker B; Krauss M; Bulla M; Cochat P; Fehrenbach H; Fischer W; Foulard M; Hoppe B; Hoyer PF; Jungraithmayr TC; Klaus G; Latta K; Leichter H; Mihatsch MJ; Misselwitz J; Montoya C; Müller-Wiefel DE; Neuhaus TJ; Pape L; Querfeld U; Plank C; Schwarke D; Wygoda S; Zimmerhackl LB
    Transplantation; 2008 Nov; 86(9):1241-8. PubMed ID: 19005406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rescue immunosuppressive therapies in living-related renal allotransplant: a long-term prospective randomized evaluation.
    Bakr MA; Gheith OA; Ismael AM; Baz ME; Shehab El-Dein AB; Ghoneim MA
    Exp Clin Transplant; 2008 Mar; 6(1):48-53. PubMed ID: 18405245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients.
    Phanish MK; Hull RP; Andrews PA; Popoola J; Kingdon EJ; MacPhee IAM;
    BMC Nephrol; 2020 Mar; 21(1):92. PubMed ID: 32160893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation.
    Hamdy AF; El-Agroudy AE; Bakr MA; Mostafa A; El-Baz M; El-Shahawy el-M; Ghoneim MA
    Am J Transplant; 2005 Oct; 5(10):2531-8. PubMed ID: 16162204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Steroid withdrawal at 3 months after kidney transplantation: a comparison of two tacrolimus-based regimens.
    Wlodarczyk Z; Walaszewski J; Perner F; Vitko S; Ostrowski M; Bachleda P; Kokot F; Klinger M; Szenohradszky P; Studenik P; Navratil P; Asztalos L; Rutkowski B; Kalmar KN; Hickey D
    Transpl Int; 2005 Feb; 18(2):157-62. PubMed ID: 15691267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up.
    Lee YJ; Kim B; Lee JE; Kim YG; Kim DJ; Kim SJ; Joh JW; Oh HY; Huh W
    Transpl Int; 2010 Feb; 23(2):147-54. PubMed ID: 19744223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one-year results of a 2-center prospective randomized trial.
    Zuckermann A; Reichenspurner H; Birsan T; Treede H; Deviatko E; Reichart B; Klepetko W
    J Thorac Cardiovasc Surg; 2003 Apr; 125(4):891-900. PubMed ID: 12698153
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant.
    Pascual J; van Hooff JP; Salmela K; Lang P; Rigotti P; Budde K
    Transplantation; 2006 Jul; 82(1):55-61. PubMed ID: 16861942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteinuria among primarily sirolimus treated live-donor renal transplant recipients' long-term experience.
    Hamdy AF; Bakr MA; Ghoneim MA
    Exp Clin Transplant; 2010 Dec; 8(4):283-91. PubMed ID: 21143093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
    Martin ST; Roberts KL; Malek SK; Tullius SG; Vadivel N; De Serres S; Grafals M; Elsanjak A; Filkins BA; Chandraker A; Gabardi S
    Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of one-year follow-up of steroid-free immunosuppression in pediatric renal transplant patients.
    Silverstein DM; Aviles DH; LeBlanc PM; Jung FF; Vehaskari VM
    Pediatr Transplant; 2005 Oct; 9(5):589-97. PubMed ID: 16176415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Daclizumab in combination with mycophenolate mofetil and a late introduction of Tacrolimus at low doses, as a therapeutic approach in the elderly renal transplant donor-recipients pairs in kidney transplant].
    Gentil MA; Osuna A; Capdevilla L; Cantarell C; Pereira P; Mazuecos A; González Molina M
    Nefrologia; 2008; 28(3):287-92. PubMed ID: 18590495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation.
    Takada Y; Kaido T; Asonuma K; Sakurai H; Kubo S; Kiuchi T; Inomata Y; Isaji S; Tsumura H; Teramukai S; Matsubara Y; Sakabayashi S; Uemoto S
    Liver Transpl; 2013 Aug; 19(8):896-906. PubMed ID: 23696054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Basiliximab induction in renal transplantation: long-term outcome.
    Atlani M; Sharma RK; Gupta A
    Saudi J Kidney Dis Transpl; 2013 May; 24(3):473-9. PubMed ID: 23640617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
    Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience.
    Aw MM; Taylor RM; Verma A; Parke A; Baker AJ; Hadzic D; Muiesan P; Rela M; Heaton ND; Mieli-Vergani G; Dhawan A
    Transplantation; 2003 Mar; 75(6):796-9. PubMed ID: 12660504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term study of steroid avoidance in renal transplant patients: a single-center experience.
    Nagib AM; Abbas MH; Abu-Elmagd MM; Denewar AA; Neamatalla AH; Refaie AF; Bakr MA
    Transplant Proc; 2015 May; 47(4):1099-104. PubMed ID: 26036529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.